Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.

Content Provider	Europe PMC
Author	Fan, Limei Tian, Muyou Liu, Yunyi Deng, Ying Liao, Zhengkai Xu, Jinhua
Copyright Year	2017
Abstract	In this study, we investigated anti-tumor activity and associated molecular mechanism of action of Salicylate ●Phenanthroline Copper (II) Complex in triple-negative breast cancer. Salicylate ●Phenanthroline Copper (II) Complex inhibited the growth of four breast cancer cell lines (MCF-7, T47D, MDA-MB-231 and BT-20) and induced apoptosis in a concentration-dependent manner. The effect was more profound in MDA-MB-231 and BT-20 triple-negative breast cancer cell lines. Western blot showed that the expression of the apoptosis-related protein Bcl-2, Bcl-xl and survivin was significantly reduced in MDA-MB-231 after treatment with Salicylate ●Phenanthroline Copper (II) Complex. In vivo, Salicylate ●Phenanthroline Copper (II) Complex administration significantly attenuated tumor growth of MDA-MB-231 xenografts, and the expression levels of Bcl-2, Bcl-xL and survivin were reduced as measured by immunohistochemical staining. These data suggest that Salicylate ●Phenanthroline Copper (II) Complex is a promising novel therapeutic drug for triple-negative breast cancer and warrants further study.
Journal	Oncotarget
Volume Number	8
PubMed Central reference number	PMC5444706
Issue Number	18
PubMed reference number	28415735
e-ISSN	19492553
DOI	10.18632/oncotarget.16161
Language	English
Publisher	Impact Journals LLC
Publisher Date	2017-05-01
Access Restriction	Open
Rights License	This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. Copyright: © 2017 Fan et al.
Subject Keyword	TNBC Cu(sal)(phen) cell growth apoptosis anti-apoptotic protein
Content Type	Text
Resource Type	Article
Subject	Oncology